BriaCell Therapeutics Corp. (BCTX)
Nasdaq · Healthcare · Biotechnology
$4.18+3.47%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $36.4M
- 52-week range
- $2.60 – $14.68
- 52-week change
- −69.44%
- EPS (trailing)
- −$0.92
Fiscal year to Jul 2025
- Net income
- −$26.3M
- Diluted EPS
- −$62.19
From the company’s annual report on SEC EDGAR.
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Headquarters: West Vancouver, Canada · briacell.com